Bioasis Technologies, Inc . (OTCQB:BIOAF) (CVE:BTI) CEO Deborah Rathjen sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Guilford, Connecticut-based company is developing a proprietary technology to delivery therapeutics across the blood brain barrier and treating CNS disorders in brain cancers and neurodegenerative diseases.
Bioasis Technologies secures patents in key global markets
Quick facts: Bioasis Technologies Inc.
Price: 0.3566 USD
Market Cap: $24.24 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE